Attention Investors: Epix Under Scrutiny

A Warning from Bronstein, Gewirtz & Grossman LLC

February 28, 2025

NEW YORK, NY – Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, has issued a notification to investors regarding a class action lawsuit that has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ:EPIX) and certain of its officers.

Class Definition: This lawsuit aims to recover damages against Defendants for alleged violations of federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023, and October 31, 2024, both dates inclusive (the “Class Period”).

Investors should take note of the scrutiny surrounding Epix and the potential repercussions it may have on their investments. The allegations of violations of securities laws raise concerns about the company’s practices and may lead to significant financial consequences.

It is essential for investors to stay informed and seek legal counsel if they have been affected by the actions of ESSA Pharma Inc. and its officers. Bronstein, Gewirtz & Grossman LLC will continue to provide updates on this class action lawsuit as it progresses.

Stay tuned for more information and be vigilant in protecting your investments during times of uncertainty and legal challenges in the financial markets.

Impact on Individuals:

Individual investors who have purchased ESSA securities during the specified Class Period may face financial losses as a result of the alleged violations of securities laws. It is crucial for affected individuals to take action and seek legal advice to protect their investments and rights.

Impact on the World:

The scrutiny and class action lawsuit against ESSA Pharma Inc. can have broader implications for the financial markets and investor confidence. Instances of alleged violations of securities laws can erode trust in companies and impact market stability, highlighting the importance of transparency and compliance in the corporate world.

Conclusion:

Investors should be wary of the ongoing scrutiny surrounding ESSA Pharma Inc. and the class action lawsuit filed against the company and its officers. Seeking legal counsel and staying informed about developments in this case is crucial for safeguarding investments and upholding integrity in the financial markets.